Women’s health matters: Unlocking investment opportunities beyond IVF

In 2023, the global women’s health market was valued at US$250-300 billion and is forecasted to reach US$500 billion by 2030, demonstrating a compound annual growth rate (CAGR) of approximately 10%. The market encompasses not only reproductive health but also cardiovascular diseases, osteoporosis, endocrine disorders, and mental health. Fueled by unmet medical needs and rapid innovation, the sector is primed for substantial expansion. This report provides a comprehensive analysis of the market’s current landscape, including its definition, key therapeutic areas, investment rationale, and notable transactions.​

Key Observations from Recent Transactions:​

• Enhanced Awareness Boosting Market Growth: Increasing awareness of women’s health issues is amplifying the market’s potential. This growing consciousness spans a comprehensive array of health conditions impacting women, not just limited to reproductive health, but significantly broadening the market’s scope​
• Strategic Expansion and Investment by Major Corporations and Venture Capitals: Major corporations are solidifying their foothold in the women’s health arena through strategic mergers, acquisitions, and partnerships, particularly focusing on cutting-edge technologies. Simultaneously, venture capital firms are actively supporting startups with convertible bonds and growth equity. Additionally, the investment focus has expanded from traditional sectors like reproductive health, contraception, and fertility treatments to include broader areas. This shift signifies a deeper appreciation of the varied healthcare needs of women throughout their life cycle​
• Innovation-Driven Growth: The market is characterized by continual innovation, with the introduction of new FDA-approved medical devices for treating conditions like uterine fibroids, and cervical and breast cancers. Developments in FemTech, telemedicine, wearable technology, and AI-driven diagnostics are transforming the sector, creating new avenues for growth​

The women’s health sector is experiencing a profound transformation, characterized by market expansion and significant economic potential. Strategic partnerships and technological innovations remain the primary catalysts for growth. Despite facing historical underfunding and other challenges, the industry is set to make substantial progress by capitalizing on global opportunities to enhance comprehensive healthcare for women worldwide.

Download full report here

About BDA Partners

BDA Partners is the global investment banking advisor for Asia. We are a premium provider of Asia-related advice to sophisticated clients globally, with 30 years of experience advising on cross-border M&A, capital raising, and financial restructuring. We provide global reach with our teams in New York and London, and true regional depth through our seven Asian offices in Mumbai, Singapore, Ho Chi Minh City, Hong Kong, Shanghai, Seoul and Tokyo. BDA has deep expertise in the Chemicals, Consumer & Retail, Health, Industrials, Services, Sustainability and Technology sectors. We work relentlessly to earn our clients’ trust by delivering insightful advice and outstanding outcomes.

BDA Partners has strategic partnerships with William Blair, a premier global investment banking business, and with DBJ (Development Bank of Japan), a Japanese Government-owned bank with US$150bn of assets.

US securities transactions are performed by BDA Partners’ affiliate, BDA Advisors Inc, a broker-dealer registered with the Securities and Exchange Commission (SEC). BDA Advisors Inc is a member of the Financial Industry Regulatory Authority (FINRA) and SIPC. In the UK, BDA Partners is authorized and regulated by the Financial Conduct Authority (FCA). In Hong Kong, BDA Partners (HK) Ltd is licensed and regulated by the Securities & Futures Commission (SFC) to conduct Type 1 and Type 4 regulated activities to professional investors. www.bdapartners.com